Please login to the form below

Not currently logged in
Email:
Password:

UDG Healthcare’s Chris Corbin to retire

CEO of Ashfield Commercial & Medical Services to step down in 2019

Ashfield Chris CorbinChief executive officer of Ashfield Commercial & Medical Services Chris Corbin is to retire from his post in April 2019.

Corbin will transfer to the role of chairman of Ashfield - part of the UDG Healthcare group - once his successor has been appointed in order to facilitate a phased transition of responsibilities over the next two years.

Corbin co-founded Ashfield Healthcare, a UK contract sales organisation, with his wife Samantha Corbin in 1996, and the firm became part of the UDG group in 2000.

He has served as a main board director of UDG Healthcare since then, growing Leicester-based Ashfield to encompass eight units with 5,500 employees across 20 countries worldwide.

Brendan McAtamney, chief executive of UDG Healthcare, said: “I would like to thank Chris for his substantial contribution to the success of both the group and Ashfield since joining us in 2000.

“Under his leadership, Ashfield has developed into a leading international healthcare services organisation and a key division of the group.

“We will work closely with Chris over the next two and a half years to ensure a professional transition process and thereafter wish him the very best in retirement.”

3rd October 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics